Clinical and epidemiological studies provide support that the polyunsaturated omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid from fish and fish oils are cardioprotective, particularly in the setting of secondary prevention. Omega-3 fatty acids benefit multiple cardiometabolic risk factors including lipids, blood pressure, vascular reactivity and cardiac function, as well as having antithrombotic, anti-inflammatory and antioxidative actions. Omega-3 fatty acids do not associate with any adverse effects and do not adversely interact with prescriptive drugs such as lipid-lowering, antihypertensive or hypoglycaemic medications. Clinical studies suggest that doses up to 4g daily when prescribed with anticoagulant or antiplatelet drugs do not associate with increased risk of major bleeding episodes. Omega-3 fatty acids have gained widespread usage by general practitioners and clinicians in clinical settings such as pregnancy and infant development, secondary prevention in coronary heart disease patients and treatment of dyslipidaemias.
INTRODUCTION
Observational studies first reported in the 1970s showed that the Greenland Inuit population had a low incidence of coronary artery disease that was related to their traditional lifestyle and in particular their distinctive dietary habits [1] [2] [3] . The Inuit population was found to have a reduced prevalence of other chronic and inflammatory diseases such as arthritis, psoriasis, asthma and diabetes. The traditional Greenland Inuit diet derived its main energy source from cold water marine fish and artic mammals such as seal and whale. Thus in comparison with a typical Western diet, it contained much higher protein and fat (approx 40% energy) and lower carbohydrates 2 , but also substantially higher amounts of omega-3 (3) polyunsaturated fats, particularly eicosapentaenoic acid (EPA, 20:53) and docosahexaenoic acid (DHA, 22:63),
rather than omega-6 polyunsaturated fats such as linoleic acid (18:26) and arachidonic acid (20:46) that are characteristic of Western diets. These differences in dietary fats were consistent with the plasma fatty acid profile of the Inuit population. The metabolic consequences of the Inuit diet included a more favourable lipid and lipoprotein profile, typically lower levels of triglycerides, cholesterol, low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C), and higher concentrations of high density lipoprotein cholesterol (HDL-C); prolongation of bleeding times; reduced platelet aggregability and thrombosis; and altered eicosanoid profile due to the higher plasma EPA and reduced arachidonic acid levels 1-3 .
3 FATTY ACIDS: SOURCES, BIOCHEMISTRY AND METABOLISM
3 and  Fatty acids are essential polyunsaturated fatty acids derived from linoleic acid shown to be generally less biologically active than those from arachidonic acid 4 , or they antagonise the action of those metabolites derived from arachidonic acid 5 .
Western diets are abundant in  fatty acids, mainly derived from vegetable oils rich in linoleic acid. -Linolenic acid is found in some plant oils particularly linseed oil (~53%), rapeseed oil (canola oil contains ~10%), soybean oil (~7%) and walnut oil (~10%). Humans lack the necessary enzymes to convert  fatty acids to 3 fatty acids and have a limited capacity (<1%) to convert -linolenic acid to EPA and DHA 6 . Thus the main dietary source of 3 fatty acids is fish especially oily fish species, shell fish and fish oils.
The lipid composition of fish is highly variable between fish species. Diet, season, latitude, temperature, age, sex and size, also influence lipid content and composition. Fish species with relatively high 3 fatty acid content include oily fish such as mackerel, salmon, cod, mullet, herring and flounder 7 .
Since these reports of more forty years ago numerous population studies and clinical trials, as well as animal experimental studies, have examined the role of 3 fatty acids in various disease states. The purpose of this review is to examine the evidence for an effect of 3 fatty acids, specifically EPA and DHA, on cardiovascular disease in humans. Data from in vitro and animal studies will be considered where it assists to understand possible mechanisms of action of 3 fatty acids. The review will not address any potential effects of -linolenic acid.
3 FATTY ACIDS: EVIDENCE FROM POPULATION STUDIES AND RANDOMISED CONTROLLED TRIALS Population Studies
A number of population studies have demonstrated an inverse association between consumption of 3 fatty acids as fish or fish oils and cardiovascular disease. These findings have been confirmed in several meta-analyses [8] [9] [10] [11] [12] [13] [14] In contrast to the above analyses demonstrating benefit, Rizos et al 15 reported 3 fatty acids did not associate with a lower risk of all-cause mortality, cardiac death, sudden death, myocardial infarction or stroke, in a meta-analysis comprising 20 studies of 68,680 patients.
The observed effect was not associated with study specific or population-specific characteristics. Although the relative risks for cardiac death and sudden death were 0.91 (P=0.01) and 0.87 (P=0.06), respectively, the authors adopted a conservative statistical approach and inexplicably set the p-value for significance at 0.0063. Two other recent meta-analyses have shown no overall benefits of 3 fatty acids on cardiovascular events 16, 17 .
Population studies have shown that increased consumption of 3 fatty acids as fatty fish associated with lower rates of heart failure, albeit unexpectedly in one study the relationship was U-shaped suggesting higher consumption did not provide additional benefit 18 . Djousse et al 19 , in a meta-analysis comprising 176,441 subjects and 5,480 incident cases of heart failure from 7 prospective studies, showed the pooled relative risk for heart failure comparing the highest to lowest category of fish intake was 0.85 (p=0.04) and for 3 fatty acids was 0.86 (p=0.05). Mozaffarian et al 20 showed consumption of tuna or other broiled or baked fish, but not fried fish associated with a lower incidence of heart failure.
The effects of 3 fatty acids on atrial fibrillation in population studies are equivocal with some studies showing benefit [21] [22] [23] whilst others have shown no effect 24, 25 The reasons for divergent results between studies are not clear but may relate to a number of important factors. Firstly, 3 fatty acids may well provide greater benefit to patients with recent myocardial infarction or heart failure due to their antiarrhythmic effects.
Secondly, it may be that some studies have had limited power to detect a reduction in sudden deaths from cardiac causes or arrhythmic events. Other important factors include studies using doses of 3 fatty acids that are lower than the 800-900 mg/day previously shown to have an effect, the presence of confounding comorbidities, effects of concomitant medications and the likelihood that recent studies have included patients that are already receiving a high level of clinical care. Results may also be confounded by the effects of dietary background, particularly in relation to 3 fatty acid intake. In this regard, studies may have included participants with a relatively high intake of 3 fatty acids. Such participants would likely have higher cellular levels of 3 fatty acids levels, thus limiting the likelihood of detecting additional benefits of 3 fatty acid supplementation. Some investigators have also suggested cardiovascular benefits may be dependent on the ratio of dietary  to 3 fatty acids.
However, Harris et al 37 showed absolute intake of 3 fatty acids is more important than the ratio of their intake to  fatty acids. Harris et al 37 also suggested tissue 3 fatty acid levels are more prognostic and diagnostic in coronary artery disease assessment.
3 FATTY ACIDS AND CARDIOMETABOLIC RISK FACTORS
There is considerable evidence that EPA and DHA have independent effects on numerous physiological pathways, and collectively they provide protection against CHD, particularly sudden coronary death [38] [39] [40] [41] . EPA and DHA beneficially affect multiple cardiometabolic risk factors including blood pressure [42] [43] [44] [45] and cardiac function 41, 44 , arterial compliance 46, 47 , vascular reactivity 48, 49 and lipids 50, 51 , as well as having anti-platelet 52 ,
anti-inflammatory [53] [54] [55] , pro-resolving 56 and anti-oxidative actions 57 . Trials in humans using highly purified oils have also highlighted that EPA and DHA have differential effects on blood pressure, heart rate, lipids and vascular reactivity 58 .
The following sections review the effects of 3 fatty acids on cardiometabolic risk factors, concentrating particularly on evidence from randomised controlled studies in humans.
Some data from experimental and animal studies will be considered where it assists to understand possible mechanisms of action of 3 fatty acids.
Plasma Lipids
 3 Fatty acids reduce triglycerides in a dose-dependent manner across a wide range of 3 fatty acid consumption 41 . Intakes of approximately 4g/day reduce serum triglycerides by 25-30%. Mozaffarian et al 41 determined that plasma triglycerides are reduced by 0.33mmol/L for a 1g/day increase in EPA plus DHA. In trials supplementing highly purified EPA or DHA,
Mori et al 59, 60 further showed the triglyceride-lowering actions of 3 fatty acids were attributable to both EPA and DHA. High-doses of 3 fatty acids can be useful as adjunct therapy in the treatment of hypertriglyceridaemia.
The fall in plasma triglycerides following 3 fatty acid consumption is due in part to a reduction in hepatic very-low density lipoprotein cholesterol (VLDL) synthesis. Mechanisms for this effect include reduced fatty acid availability for triglyceride synthesis as a result of decreased de novo lipogenesis, a reduction in the delivery of non-esterified fatty acids to the liver, increased fatty acid -oxidation, altered enzymatic activity for triglyceride assembly in the liver, and increased hepatic synthesis of phospholipids instead of triglycerides 50, 51, 61 .
Cussons et al 62 also showed that 3 fatty acids significantly reduced liver fat by 18% in women with hepatic steatosis.
3 Fatty acids have very little effect on total cholesterol and LDL-C 50, 51 . However,
Mori et al showed in overweight, treated hypertensive patients 63 and in dyslipidaemic men 59 , that 3 fatty acids had a small, albeit significant effect on increasing HDL-C, due primarily to an increase in the HDL 2 -C subfraction.
A small, but significant increase in LDL-C in studies supplementing 3 fatty acids associated with an increase in LDL particle size. Mori et al 59, 64 showed that DHA but not EPA supplementation increased LDL particle size. Studies have shown that reduced LDL particle size is an important cardiovascular risk factor 65 that correlates with sub-clinical atherosclerosis as measured by intima-media thickening 66 .
A number of clinical trials have shown that 3 fatty acids may compliment lipid lowering therapy in dyslipidaemic patients. Chan et al 67 showed in dyslipidaemic, viscerally obese men with insulin resistance, that supplementation with 3 fatty acids in addition to statin therapy resulted in optimal changes in lipid profile as reflected by decreased plasma triglycerides and increased HDL-C.
Blood Pressure

Meta-Analyses
Randomised controlled trials in which participants have been provided fish meals or
supplemented fish oils unequivocally demonstrate that 3 fatty acids lower blood pressure.
Three meta-analyses have investigated the effect of 3 fatty acids on blood pressure 42, 43, 45 .
In an analysis of 31 placebo controlled trials involving 1,536 subjects, Morris et al 45 
3 Fatty Acids and Antihypertensive Medication or Lifestyle Modification
It is noteworthy that not all studies have demonstrated a reduction in blood pressure with consumption of fish or 3 fatty acid supplementation. The reasons for this are likely related to differences in study design, the protocol and choice of instrument used for blood pressure assessment, studies with relatively small sample size leading to a lack of statistical power and/or studies that have employed a dose of 3 fatty acids not sufficiently high to elicit an effect. In regard to the latter, Dokholyan et al 68 reported low doses of 3 fatty acids were ineffective in reducing blood pressure in patients with high-normal diastolic blood pressure or stage 1 hypertension. The authors concluded that doses greater than 3g/day 3 fatty acids are required for blood pressure reduction. fatty acids, the two regimens combined, or a control diet, for 12 weeks. At the end of this period all subjects were placed on a weight-stabilizing diet for 4 weeks and continued on fish if they were in those groups. Weight fell on average 5.6 kg in the two weight-loss groups.
Blood pressure was determined using 24-hour blood pressure measurements. Relative to the control group, awake blood pressures fell -6.0/-3.0 mmHg in those patients consuming a daily fish meal, -5.5/-2.2 in the weight loss group and -13.0/-9.3 in individuals that combined the two regimens. weeks, significantly reduced 24-hour blood pressure by -5.8/-3.3 mmHg and awake blood pressure by -3.5/-2.0 mmHg, relative to a control oil (olive oil). These differences in blood pressure response to EPA and DHA were not observed in normotensive healthy men who were given 4g daily EPA or DHA for 7 weeks, relative to a corn oil control 75 . The latter study, however, measured clinic and not 24-hour blood pressure. Woodman et al 60 were also unable to confirm a differential effect of EPA and DHA on blood pressure in treated hypertensive Type 2 diabetic patients. Neither highly purified encapsulated EPA nor DHA given as a 4g daily supplement for 6 weeks reduced 24-hour blood pressure. However, this lack of effect on blood pressure in treated hypertensive Type 2 diabetic patients could be related to concomitant use of pharmacologic agents, the presence of glycaemia and increased blood pressure variability in diabetic patients.
Endothelial and Vascular Function
Data from experimental animal models of endothelial dysfunction 48, 76, 77 The effects of 3 fatty acids, particularly those of DHA on vasoreactivity are, in part, due to incorporation of 3 fatty acids into endothelial membranes with consequent increase in membrane fluidity, calcium influx, and endogenous synthesis and release of nitric oxide.
Incorporation of 3 fatty acids into cell membranes could be expected to affect fluidity, flexibility, permeability and function of the membrane and membrane-bound proteins. These changes could in turn alter enzyme activity, receptor affinity and transport capacity of the cell, including synthesis and/or release of nitric oxide. Hashimoto et al 84 showed DHA had a greater effect than EPA in increasing membrane fluidity of cultured rat thoracic aorta endothelial cells.
Experimental evidence has shown 3 fatty acids may have direct effects on receptorstimulated nitric oxide release, as well as enhanced release of vasodilator prostanoids and/or endothelial-derived hyperpolarizing factor 85 . Enhanced vasodilator response to sodium nitroprusside could also be related to increased biotransformation to nitric oxide or increased reactivity of smooth muscle cells to vasorelaxation as a result of decreased calcium influx 86 .
The vasodilator effects of 3 fatty acids and DHA in particular, may be related to increased basal production of nitric oxide in smooth muscle cells as a result of decreased release of platelet-derived growth factor (PDGF) 87 . PDGF inhibits induction of nitric oxide synthase in vascular smooth muscle cells 88 .
Animal studies suggest the blood pressure-lowering effects of 3 fatty acids may relate to their effects on catecholamines and ATP. Hashimoto et al 89 showed that DHA fed intragastrically to Wistar rats reduced plasma noradrenaline and increased adenyl purines such as ATP, released both spontaneously and in response to noradrenaline from segments of caudal artery. These rats had 44% lower plasma noradrenaline and attenuated blood pressure.
Plasma adenyl purines were significantly inversely associated with blood pressure. The relevance of these data is in the knowledge that ATP causes vasodilation by stimulating the release of nitric oxide from endothelial cells, by a direct action on vascular smooth muscle cells and by hyperpolarizing smooth muscle cells. Therefore, the increase in ATP release from vascular endothelial cells in conjunction with reduced plasma noradrenaline could contribute to the fall in blood pressure following 3 fatty acids.
Arterial Compliance
Blood pressure is strongly influenced by arterial compliance, which in turn is affected by endothelial function. Arterial compliance is also an independent risk factor for cardiovascular disease 90 . Studies have shown that 3 fatty acids improve arterial compliance.
In Type 2 diabetic patients McVeigh et al 46 showed that compliance in the large arteries and more peripheral vasculature improved significantly after 6 weeks of fish oil compared with olive oil. Nestel et al 47 also showed that EPA and DHA supplementation improved arterial compliance by 35% and 27%, respectively, in patients with dyslipidaemia. In a meta-analysis that included ten randomized controlled trials, four using pulse wave velocity and six using arterial compliance measured as capacitance compliance or systemic arterial compliance, Pase et al 91 showed that 3 fatty acids significantly improved both pulse wave velocity and arterial compliance.
Cardiac Function
Heart Rate
Increased heart rate is a risk factor for cardiovascular death, particularly sudden death 92 . Studies have consistently shown that 3 fatty acids reduce heart rate 44, 73, 74, 93 suggesting a significant cardiac component associated with the antihypertensive effects, possibly mediated by effects on cardiac myocytes, autonomic nerve function or -adrenoreceptor activity.
Using 24-hour measurement of heart rate, Bao et al 73 showed in overweight treated hypertensive patients, that awake heart rate was reduced by 4.3 bpm by a daily fish meal, 1.8 bpm following weight loss and 6.1 bpm by a combination of the two regimens, relative to controls. In subsequent studies Mori et al 74 have shown that heart rate is differentially affected by EPA and DHA. DHA, but not EPA, significantly reduced 24 hour, awake and asleep heart rate by -3.5, -3.7 and -2.8 bpm, respectively 74 . Interestingly, EPA resulted in a small, albeit non-significant, rise in heart rate. These data are in accordance with those of Grimsgaard et al 75 in which heart rate was decreased by 2.2 bpm with 4g daily DHA supplementation and increased by 1.9 bpm with EPA.
In a meta-analysis of thirty studies, Mozaffarian et al 93 showed that the overall effect of 3 fatty acids was to reduce heart rate by -1.6 bpm, with a greater reduction in those trials where individuals had a baseline heart rate greater than 69 bpm (-2.5 bpm) and in those studies of longer than 12 weeks duration (-2.5 bpm).
Experimental studies have shown that the mechanisms by which 3 fatty acids affect heart rate likely relate to their incorporation into myocardial cells and subsequently altering electrophysiological function in a manner that reduces the vulnerability to ventricular fibrillation 94 . The anti-arrhythmic effects of 3 fatty acids are due to their ability to inhibit the fast, voltage-dependent sodium current and the L-type calcium currents, and also to modulate potassium channels 94 .
Heart Rate Variability
Studies in humans suggest that 3 fatty acids increase heart rate variability in patients at high risk of sudden cardiac death and in healthy individuals 95, 96 . Heart rate variability is a surrogate index of autonomic nerve function and low heart rate variability independently predicts cardiovascular disease mortality in patients with coronary artery disease or chronic heart failure 97, 98 and in healthy populations 99 . Xin et al 100 in a meta-analysis that included fifteen randomised controlled trials showed that short term 3 fatty acid supplementation favourably affects the frequency domain of heart rate variability as indicated by enhancement of vagal tone. These data suggest enhanced vagal tone may be an important mechanism underlying the antiarrhythmic effect of 3 fatty acids.
Platelet Function and Thrombosis
The inhibitory effects of  fatty acids on thrombosis are thought to account partially for the associated reduced risk for sudden cardiac death and reduced all-cause mortality 9, 30, 31 . The antithrombotic and antiplatelet effects of 3 fatty acids are due to modulation of vasodilator and vasoconstrictor prostanoids 52 . Reduced platelet aggregation in vitro following 3 fatty acids, particularly at large doses, is likely due to suppressed production of thromboxane A 2 (TXA 2 ) a vasoconstrictor and aggregator 101 . Knapp et al 102 showed that in patients with atherosclerosis 3 fatty acids decreased TXA 2 and increased thromboxane A 3 (TXA 3 ) the analogous but substantially less biologically active EPA-derived metabolite.
Fischer et al 103 reported 3 fatty acids increased prostaglandin I 3 (PGI 3 ) (also known as prostacyclin) derived from EPA, without a fall in prostaglandin I 2 (PGI 2 ) which derives from arachidonic acid. PGI 3 is equipotent in its vasodilatory and anti-aggregatory activities to PGI 2 .
It has been suggested that an overall increase in total prostacyclin (PGI 2 and PGI 3 ) formation in conjunction with reduced total thromboxane (TXA 2 and TXA 3 ), could favourably alter thrombotic, endothelial and vascular responses following dietary 3 fatty acids.
Improvements in blood rheology 104 and reduced PDGF-like proteins 105 following 3 fatty acids could contribute to a decrease in clinical atherothrombosis.  Fatty acids have shown inconsistent and minor effects on measures of fibrinolysis and coagulability 106, 107 .
In spite of the in vitro evidence that 3 fatty acids have antithrombotic effects, it is currently thought that any benefits are more likely related to their antiarrhythmic rather than antihrombotic effects 106 . This hypothesis is supported with the knowledge that cardiovascular clinical benefits of 3 fatty acids have been noted with doses as low as 1g/day 31, 32 whilst changes in platelet aggregation have generally been observed at higher doses.
Mori et al 108 showed that dietary fish and fish oils reduced platelet aggregation and platelet thromboxane formation. ω3 Fatty acid effects on platelet aggregation were also influenced by the background level of dietary fat, the source of the ω3 fatty acids and the agonist used to induce platelet aggregation. Dietary ω3 fatty acids reduced platelet TXA 2 release from collagen-aggregated platelets 108 . Although platelet aggregation was reduced in response to all doses of collagen and PAF following ω3 fatty acids, the effect was more pronounced at doses of each agonist close to the threshold dose for aggregation.
Independent Effects of EPA and DHA
In a double-blind placebo-controlled trial of parallel design, Woodman et al 109 examined for differential effects of purified EPA and DHA on platelet function in treatedhypertensive Type 2 diabetic men and postmenopausal women. Participants were randomised to 4g daily EPA, DHA or olive oil for 6 weeks. Relative to placebo, DHA but not EPA supplementation significantly reduced collagen-induced aggregation and TXB 2 but there was no significant change in PAF-stimulated platelet aggregation.
Inflammation
  Fatty acids have potent anti-inflammatory and immunomodulatory effects that
operate through multiple mechanisms including attenuating formation of inflammatory eicosanoids and leukotrienes, cytokines, oxidative stress, and altering endothelial and cell-cell activation, and immune cell function [53] [54] [55] .
 Fatty acids have been shown to alter production of the leukotrienes (LT) 54 . EPA is a preferred substrate of the lipoxygenase pathway leading to the production of the relatively inactive LTB5 at the expense of LTB4 which is derived from arachidonic acid; the latter is a potent chemotactic factor for leukocytes [53] [54] [55] . Increased generation of neutrophil-derived LTB5 has been demonstrated following intake of  fatty acids in humans 110, 111 . The formation of LTB5 in place of LTB4 following consumption of  fatty acids likely plays an important role in attenuating the inflammatory process.
A number of studies have shown 3 fatty acids reduce ex vivo formation of proinflammatory cytokines such as TNF-, IL-1 and IL-6 following stimulation of monocytes/lymphocytes with lipopolysaccharide [53] [54] [55] . In-vitro studies have also shown  fatty acids decreased the expression of pro-inflammatory cytokines, cell-adhesion molecules and monocyte adhesion to endothelial cells 112 . DHA was more potent than EPA in inhibiting expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin, after stimulation. The EPA and DHA-induced attenuation in adhesion molecule expression was accompanied by decreased binding of human lymphocytes and monocytes to cytokine-stimulated endothelial cells 112 .
Resolvins, Protectins and Maresins
There is emerging evidence that resolution of inflammation is an active process accompanied by the biosynthesis of potent lipid mediators that stimulate resolution with consequent return to tissue homeostasis. Serhan et al 56 have described several families of chemically and functionally distinct mediators, including E-series resolvins derived from EPA via P450 metabolism or aspirin-acetylated cyclooxygenase (COX-2), and D-series resolvins, protectins/neuroprotectins and maresins derived from DHA via lipoxygenase or aspirin acetylated COX-2 [113] [114] [115] [116] . These mediators act via G-coupled protein receptors 117 and have potent anti-inflammatory and pro-resolving actions 118, 119 that increase with time during the inflammatory process 56, 120 . Studies have shown they reduce airway inflammation 121 , colitis 122 , arthritis 123 and post-operative pain 124 . The resolvins from 3 fatty acids are orders of magnitude more potent than the lipoxins derived from arachidonic acid.
Mas et al 125 have shown that 18R/S-HEPE and 17R/S-HDHA, the resolvin and protectin pathway precursors, as well as the resolvins 17S-RvD2, 17S-RvD1 and 17R-RvD1, were increased in human plasma following  fatty acid supplementation, at concentrations known to have potent anti-inflammatory effects.
Effects on Plaque Stabilization
The antithrombotic and anti-inflammatory effects of 3 fatty acids play an important role in preventing plaque development and may assist in plaque stabilization. Thies et al 126 showed that following supplementation, 3 fatty acids were readily incorporated into the atherosclerotic plaque of patients with symptomatic carotid atherosclerotic disease undergoing carotid endarterectomy. he study showed that this incorporation associated with a reduced number of macrophages in the plaque and plaque morphology suggestive of increased stability. These findings could represent an important mechanism by which 3 fatty acids reduce ischaemic cardiovascular events.
Glucose Homeostasis
Early reports suggested  fatty acids adversely affected glycaemic control, particularly in Type 2 diabetic patients. However, these findings were likely related to the study design, the high dose of  fatty acids employed, concomitant oral diabetic medication, the presence of obesity and/or insulin resistance, presence of other comorbidities such as hypertension, not controlling for background dietary intake during intervention, and duration of intervention 127 .
Three Some concerns have also been raised that 3 fatty acids could increase the risk of bleeding during major surgery, particularly in individuals consuming high supplement doses.
However, postoperative parenteral fish oil administration at a dose of 0.2 g/kg body weight after major abdominal surgery did not result in clinically significant bleeding and was considered safe with regard to coagulation and platelet function 146 . Nonetheless some clinicians routinely advise patients to discontinue fish oil supplements 4-7 days prior to invasive procedures with the highest risk for bleeding complications. Postoperatively, clinicians should consider the cardiovascular advantages of recommencing 3 fatty acid supplements in view of the fact that cardiovascular and thrombotic events are often common complications after major surgeries.
Some fish species may contain levels of methylmercury and environmental contaminants. These substances are present at low levels in fresh waters and oceans but accumulate in the aquatic food chain and are present at highest levels in predatory fish such as shark, swordfish, marlin and larger species of tuna, and marine mammals. The American Heart Association and other advisory bodies advise women who are either pregnant or may become pregnant, lactating women and young children, to limit their consumption of such fish species in order to minimize their exposure to these contaminants 147 . Association's dietary guidelines that suggest consumption of at least two 100g serves of fish per week, preferably oil fish species such as fresh tuna, salmon, mackerel, herring and sardines 147 . Fish should be broiled or baked, but not fried 20 .
Guidelines for 3 fatty acid intake
A practical recommendation for increasing 3 fatty acid intake in the general population is to incorporate fish as part of a healthy diet that includes increased consumption of fruits and vegetables, and moderation of salt intake. Patients with CHD should be encouraged to increase their EPA and DHA consumption to approximately 1g daily 147 , a figure based largely on data from clinical trials 31 . It has been suggested that 3 fatty acid supplements at doses 2-4g/day should be considered in combination with other lipid therapies in patients with hypertriglyceridaemia 147 . In view of the fact that the fetus relies on the mother for DHA, necessary for the development of the nervous system, pregnant and lactating women should aim to achieve an average dietary intake of at least 200-300 mg DHA/day 150, 151 . These doses of 3 fatty acids are now achievable with the availability of high-quality encapsulated 3 fatty acid supplements free of contaminants.
CONCLUSIONS
Current data support the concept that 3 fatty acids beneficially influence a number of cardiometabolic risk factors. 3 fatty acids have anti-atherosclerotic, antithrombotic and antiinflammatory actions. These effects likely explain the results from clinical trials that demonstrate 3 fatty acids reduce mortality and morbidity in the setting of secondary prevention, particularly in those patients surviving a myocardial infarction or with heart failure. Recently published studies in which 3 fatty acids have not shown benefit on cardiovascular endpoints are probably due to the fact that patients are now more likely to receive overall better medical care and optimal drug treatment. 3 Fatty acids do not have adverse interactions with medications such as statins and other lipid-lowering drugs, or antihypertensive and antithrombotic medications. Several issues regarding 3 fatty acids remain to be resolved, such as the optimal dose, the ratio of EPA to DHA, and their effectiveness in the setting of conventional drug therapy in different patient populations.
Small doses of 1g/day are achievable with consumption of 2-3 oily fish meals per week.
Higher doses up to at least 4g/day have no clinically significant adverse effects and are achievable with consumption of numerous purified encapsulated preparations now readily available. Overall there is sufficient evidence that increased dietary 3 fatty acids should be encouraged. In particular, fish should be considered an important component of a healthy diet and as a potential therapeutic modality in patients with coronary artery disease and those at heightened risk of cardiovascular disease 152 .
